SCHEMBL13626334

SCHEMBL13626334

CCNC(=O)c1cc(-c2ccccc2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 6/20 0.60
MCL1 Q07820 5/20 0.60
HNF4A P41235 2/20 0.60
DHFR P00374 1/20 0.60
GSTA1 P08263 1/20 0.55
HDAC1 Q13547 3/20 0.49
KDM4E B2RXH2 1/20 0.49
APOBEC3A P31941 1/20 0.49
GFER P55789 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
HDAC2 Q92769 1/20 0.48
MGLL Q99685 1/20 0.47
EGLN1 Q9GZT9 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALOX5 P09917 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12391548 0.84 PTGER4 (0.47) ACMSDMCL1HNF4ADHFREGLN1
SCHEMBL28710614 0.82 ACMSD (0.66) ACMSDMCL1HNF4ADHFRGSTA1
SCHEMBL13619747 0.80 HTR2A (0.50) HDAC1NPC1RAB9ASMN1; SMN2
SCHEMBL22445563 0.78 NAAA (0.67) KDM4EGFERALOX5CA1CA9
SCHEMBL13611930 0.78 ACMSD (0.60) ACMSDMCL1HNF4ADHFRGSTA1
SCHEMBL1797745 0.78 CA1 (0.68) KDM4ENPC1RAB9ASMN1; SMN2CA1
SCHEMBL6282455 0.78 TMPRSS4 (0.67) ACMSDMCL1HNF4ADHFRGSTA1
SCHEMBL13753913 0.77 CSNK2A1 (0.56) KDM4EEGLN1NPC1RAB9ASMN1; SMN2
SCHEMBL2070297 0.76 MCL1 (0.72) ACMSDMCL1HNF4ADHFRGSTA1
SCHEMBL4530808 0.76 NPC1 (0.63) HDAC1HDAC2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291998-A1 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF EISAI R&D MANAGEMENT CO., LTD. 2009-11-26 US disclosed
US-7524883-B2 Eponemycin and epoxomicin analogs and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291998-A1 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF PSMC4, PSMB6, EPOR ACMSD 3067/4885MCL1 356/4885HNF4A 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.